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Natural products, often containing a magnitude of unidentified constituents, have 
come under scrutiny in order to understand their effects on the human body. Cytochrome 
P450 enzymes, due to their non-selective nature, are highly susceptible to interference 
when multiple organic compounds are present in their metabolic environment. These 
enzymes are responsible for the oxidation of xenobiotic compounds, and thus play a 
crucial role in phase I drug metabolism. As part of a collaborative project at UNCG, the 
Amazonian acai berry (Euterpe oleracea) is being investigated for bioactive constituents 
based on a bioassay-guided fractionation strategy. For this study, these acai berry 
fractions underwent an inhibition-directed screening process against several in vitro 
human-model CYP450 assays. No remarkable inhibition was observed by the crude acai 
berry fractions for the CYP3A4 and 2D6 model assays. The 7-methoxycoumarin O-
demethylation assay yielded noteworthy inhibition from chloroform-extracted acai berry 
constituents. Further fractionation was successfully carried out, leading to the discovery 
of several sub-fractions with substantial inhibition. The 78-D fraction, in particular, was 
found to contain the fatty acid 1-9-hexadecenoate and gave a Ki value of 73 µM. Such 
results give strength to the implication that a number of constituents in the acai berry 
could interfere with drug metabolism of one or more cytochrome P450 isoenzymes.
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CHAPTER I 
 
INTRODUCTION 
1.1.0 Xenobiotic Metabolism 
The metabolism of xenobiotic compounds in the human body is of tremendous 
physiological significance. This process facilitates the biotransformation of lipid-soluble 
foreign molecules into polar, secretable species. This allows for the detoxification of 
potentially harmful compounds from the body
1
.This pathway is divided into two phases. 
In phase I, enzymes transform the foreign compounds primarily via oxidation, hydrolysis, 
or oxygenation. In phase II, the compounds are usually conjugated to other hydrophilic 
cellular components such as glucose, sulfate, or glutathione, which further facilitates their 
removal
2
.  
  One of the major classes of phase I enzymes is cytochrome P450 (CYP450). 
These enzymes metabolize drugs using a monooxygenase reaction shown in Equation 1. 
The active site of these enzymes contains a bound heme group, which serves to activate 
O2 and direct the transfer of an oxygen atom to a broad range of substrates
3
. A single 
CYP450 enzyme can bind to a large number of substrates, allowing for a wide breadth of 
pharmaceutical compounds to be metabolized. When a foreign compound is introduced 
into the body, its lifetime is often determined by the rate of metabolism by one or more 
CYP450 enzymes
2
. 
2 
 
RH + O2 + NADPH  ROH + H2O + NADP
+
 
Equation 1. Monooxygenase Reaction of Cytochrome P450. 
 
 
1.2.0 General Properties of Cytochrome P450 
Cytochrome P450 enzymes are a class of membrane-bound enzymes found in a 
wide range of tissue types, including hepatic and enteric tissue
4
. Distinctions between 
individual CYP450 enzymes (isozymes) are determined by their amino acid sequence, 
which can influence protein mass, active site ligand availability, and substrate 
selectivity
5
. Isozymes are typically given a three-character designation that reflects their 
classification based on gene sequence homology. For example, CYP2D6 is in the ‘2’ 
family and ‘2D’ subfamily, with the ‘6’ identifying the individual isozyme. Classification 
of the CYP450 isozymes states that isozymes share >40% homology in a family and 
>55% homology in a subfamily
6
.  
The most important aspect of CYP450 structure is the active site. Substrate 
selectivity is primarily dictated by the polarity and volume of the active site
7
. CYP3A4, 
for example, has an active site volume estimated at 950 A
3
, and can metabolize a wide 
range of substrates, such as paclitaxel (854 Da) and codeine (300 Da)
8
. CYP2A6, with a 
much smaller active site estimated at 230 A
3
, has a much more narrow range of 
substrates, including coumarin (146 Da) and nicotine (162 Da)
9
. Despite these 
distinctions, CYP450 isozymes share a highly conserved iron (III) containing porphyrin 
ring with a proximal cysteine side chain in their active sites. These analogous structures 
are important for CYP450’s role in the oxidation of organic molecules, and all isozymes 
appear to share a common catalytic cycle
10
. 
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1.2.1 Catalytic Cycle 
When a substrate is introduced to CYP450, the enzyme will initiate a 
monooxygenase reaction in which an oxygen atom that is derived from molecular oxygen 
is added to the substrate. Enzyme activity requires the presence of an auxiliary enzyme, 
CYP450 reductase, which mediates the transfer of electrons from NADPH to the heme 
complex in the active site. As illustrated in Figure 1, the active site heme is in the ferric 
state when the catalytic cycle begins (1). When an organic substrate enters the active site, 
it displaces a coordinated water molecule, causing a change in the reduction potential of 
the iron center and facilitating subsequent transfer of an electron to the ferric Fe
III
 
complex, which forms the reduced Fe
II
(2). Upon reduction, the heme complex will form a 
ferrous-dioxide species by attaching O2 to the iron center (3). The CYP450 reductase 
transfers another electron, which will again reduce the ferrous-dioxygen complex, 
transforming it into the ferric peroxo complex (4). The oxygen molecule will undergo 
protonation, followed by heterolytic O-O bond cleavage, releasing a water molecule. Left 
behind is a high valent iron-oxo complex, which enables the enzyme to now oxidize the 
substrate (5). A water molecule will replace the newly oxidized product in the active site, 
regenerating the enzyme back into the resting state (1)
11
. A proximal cysteine ligand is 
primarily responsible for assisting in the formation of the high valent iron-oxo species. 
The thiolate ligand is a good electron donor and exhibits a “push effect” on the iron atom, 
allowing for the cleavage of the O-O bond and releasing the water molecule
12
. 
 
4 
 
 
Figure 1. Catalytic Cycle of the CYP450 Monooxygenase Reaction. This catalytic 
cycle is thought to be operative in nearly all known cytochrome P450 isozymes. 
 
 
This catalytic cycle lends itself to nearly 30 different types of chemical oxidations 
that can be carried out by various CYP450 with their respective substrates. These are the 
result of the radical or concerted reaction between the high valent iron-oxo species and 
organic substrate, which can then result in a variety of spontaneous modifications after 
oxygen insertion
11
. Examples of these CYP450 reactions, hydrocarbon hydroxylation and 
heteroatom dealkylation, are described in the following sections. 
1.2.2 Hydrocarbon Hydroxylation 
 The hydroxylation of a sp3 carbon is perhaps the most basic monooxygenase 
reaction carried out by CYP450. As shown in Figure 2, the hydroxylation reaction 
involves a two-step radical pathway, sometimes referred to as the ‘oxygen rebound’ 
mechanism. The reaction begins with the alkane substrate oriented above the iron-oxo 
poryphrin ring, followed by hydrogen atom transfers, leading to the reduction of the oxo-
5 
 
ferryl group by one electron and leaving behind a radical carbon
13
. ‘Oxygen rebound’ is 
then initiated as the transfer of the hydroxyl group on the heme to the carbon radical, 
forming the final product in tandem with the final reduction of the heme, reverting the 
enzyme back to its resting ferric state
14
.  
 
Figure 2. Hydrocarbon Hydroxylation Reaction. This two-step radical reaction is 
the primary reaction of cytochrome P450.  
 
 
1.2.3 Heteroatom Dealkylation 
 
 This second type of CYP450 reaction illustrates an example of post-enzymatic 
modification. This reaction is characteristic of substrates whose target carbon is adjacent 
to an oxygen, nitrogen, or sulfur. As shown in Figure 3, the substrate will undergo normal 
hydroxylation. The proximity of the hydroxide to the neighboring heteroatom leads to 
rearrangement and subsequent dealkylation. As a result, a secondary metabolite is 
formed, typically an aldehyde
15
. 
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Figure 3. Heteroatom Dealkylation Reaction. This reaction results in the formation 
of a secondary product, which in this example is formaldehyde. 
 
 
1.3.0 Kinetics of CYP450 Activity 
 Many cytochrome P450 enzymes adhere to the Michaelis-Menten model of 
enzyme kinetics. The key indicator of faithfulness to this model is the Michaelis-Menten 
plot, which illustrates the relationship between reaction rate V and substrate 
concentration [S], as seen in Figure 4. In this model, reaction velocity follows a 
rectangular hyperbolic dependence on the substrate concentration. Eventually, the 
reaction rate will asymptotically approach a maximum threshold. This terminal velocity, 
known as the Vmax, reflects the maximum rate of product formation after complete 
saturation of available enzyme in the reaction by the substrate. Another constant in the 
Michaelis Menten plot is the Km, which is the substrate concentration when the reaction 
velocity is ½ Vmax. The Km reflects a point in the reaction where 50% of the enzyme is 
bound to substrate, and is an important consideration during optimization of the 
cytochrome P450 assays, as described in the experiment section. 
7 
 
 
Figure 4. Michaelis-Menten Plot. Illustration showing the nonlinear relationship 
between reaction rate V and substrate concentration [S], along with the 
corresponding Vmax and Km constants. 
 
 
1.3.1 Inhibition of CYP450 
 
As previously stated, cytochrome P450 serves the purpose of detoxifying the body 
of foreign organic molecules, which includes the metabolism of pharmaceutical 
compounds
1
. Like any enzyme in the body, the activity of CYP450 toward one substrate 
can be altered by the presence of a competing substrate or related compound. 
The focus of this study is on cytochrome P450 inhibition by compounds found in the 
popular superfruit acai berry. An inhibitor is any molecule that blocks the enzymatic 
metabolism of another molecule. The term ‘drug interaction’ can refer to the instance 
when the metabolism of a drug by CYP450 is inhibited, thus leading to an increase in the 
drug’s bioavailability, thus increasing the possibility of adverse drug effects. Depending 
8 
 
on how it binds to the active site, an inhibitor can be classified into one of two distinct 
categories: irreversible and reversible. 
Irreversible inhibitors, like reversible inhibitors, depend on hydrophobic and/or 
hydrophilic bonds to bind to the active site. However, these inhibitors may undergo 
activation by the enzyme and form intermediates that will covalently bind to the heme or 
amino acid residues in the active site. This form of catalysis-dependent inhibition, also 
referred to as ‘suicide inhibition’, will permanently disable the affected enzyme and 
remove it from the catalytic enzyme pool. 
A reversible inhibitor binds to CYP450 prior to substrate oxidation. For the type 
of inhibitor referred to as ‘reversible’, the effects last only as long as the inhibitor is 
present
18
. It binds to the enzyme either through lipophilic attraction to hydrophobic 
amino acids in the active site cavity or hydrogen bonding. The potency of the inhibitor 
directly corresponds with the strength of these bonds. Imadazole and pyridine-derivatives 
with nitrogen-containing aliphatic or aromatic groups typically bind tightly due to their 
high nucleophilicity, and attraction to the heme iron itself. Alcohols, ketones, and other 
oxygen-containing compounds have weaker heme-affinities and are considered weak 
reversible inhibitors. 
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1.4.0 Drug Interactions in CYP450 Isoenzymes 
Studies into cytochrome P450 inhibition is of particular concern in recent years 
due to the booming pharmaceutical industry flooding the market with thousands of 
synthetically-produced and naturally-derived drugs. It is no coincidence that, with the 
increase in prescriptions, there has been an increase in health issues caused by harmful 
drug interactions
16
. Cytochrome P450 enzymes have a ‘non-selective nature’, where 
multiple molecules have a high probability of entering and binding to the active site if 
they share similar size and polarity as substrates, leading to interactions
17
. The following 
sections highlight specific cytochrome P450 isoforms most commonly associated with 
drug interactions.  
 
1.4.1 CYP3A4 
 Cytochrome P450 3A4 plays a crucial role in human drug metabolism. CYP3A4 
enzymes are most abundant in the small intestine and liver, accounting for an estimated 
80% of the intestinal CYP450 population, and 40% of the hepatic CYP450 population, 
making it the most abundant CYP450 isozyme in the human body
17
.  The cytochrome 
P450 3A family is also highly conserved across various mammalian species. Both the rat 
CYP3A23 and rabbit CYP3A6 enzymes share structural homology with the human 
CYP3A4 enzyme. These homologs can serve as comparative models in terms of studying 
their catalytic activity and predicting effects on human CYP3A4
18
. 
With its abundance, human CYP3A4 supports a very broad selection of 
pharmaceutical substrates, and is involved in the oxidation of over 60% of the drug 
market
19
. Table 1 illustrates the vast range of drugs mediated by CYP3A4 metabolism. 
10 
 
Additionally, a list of known potent CYP3A4 inhibitors is shown. It is important to note 
that substrates of CYP3A4 can simultaneously act as inhibitors through competition with 
other substrates for the active site
20
. 
 
Table 1. List of Common Medications and Inhibitors of CYP3A4 
 
Drugs Metabolized by CYP3A4
21
 Known Inhibitors of CYP3A4
17
 
Calcium-channel blockers 
-felodipine, nifedipine 
 
Chemotherapeutics 
-paclitaxel, tamoxifen 
 
Antibiotics 
-erythromycin, clarithromycin 
 
Biosynthetic Substrates 
-testosterone 
Antifungal azole compounds 
-ketocanozole, itraconazole 
 
Antiviral protease inhibitors 
-ritonvir, saquinavir 
 
Other antibiotics 
-chloramephenicol 
-clarithromycin, telithromycin 
 
 
Drug-drug interactions, mediated by the inhibition of CYP3A4, are of particular 
concern due to the potential of adverse effects. Simvastin (Zocor), a widely prescribed 
statin-class cholesterol medication, is metabolized solely by CYP3A4. When ingested 
simultaneously with a known CYP3A4 inhibitor, simvastin will remain in the 
bloodstream longer than normal, so continued dosing can lead to elevated plasma levels. 
This increases the risk of statin-induced myopathy, causing degradation of muscle tissue 
and kidney damage through rhabdomyolysis
22
. 
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1.4.2 CYP2D6   
Cytochrome P450 2D6 is another prominent isozyme in the human body. 
CYP2D6 enzymes mainly occupy the liver, and make up approximately 10 % of the 
hepatic CYP450 pool
17
. Despite the reduced colonization in the body when compared to 
CY3A4, CYP2D6 metabolizes about 25% of the known drug market. Most notably, it is 
responsible for a wide array of drugs that cross the blood-brain barrier
23
. Table 2 lists a 
selection of known CYP2D6 substrates and inhibitors. 
 
Table 2. List of Common Medications and Inhibitors of CYP2D6. 
 
Drug Metabolized by CYP2D6
24
 Known Inhibitors of CYP2D6
23
 
Antidepressants 
-fluoxetine, paroxeitne (SSRIs) 
-bufuralol, metoprolol (beta blockers) 
-imipramine (tricyclic antidepressants) 
 
Other Psychoactive Drugs 
-dextromethorphan 
-codiene, hydrocodone, tramadol 
Other Antidepressants 
-bupropion, citralopram 
-fluxoetine, paroxetine (when combined 
with other medication) 
 
Other Drugs 
-quinidine (antiarrythmic) 
-ritonavir (protease inhibitor) 
 
 
An example of an adverse reaction to drug-drug interaction mediated by CYP2D6 
is illustrated in the following case study
25
. A patient was admitted to the emergency room 
for symptomatic hypotension after being prescribed two medications.  She was first 
prescribed paroxetine (Paxil), an SSRI-class antidepressant, to treat her anxiety and panic 
disorder.  Paroxetine also happens to be a strong inhibitor of CYP2D6
26
.  Later, after 
developing an unrelated case of hypertension, she was prescribed a high dose of 
metoprolol (Toprol XL), an agent that blocks the beta receptors on cardiovascular cells to 
12 
 
reduce stimulation. Metroprolol depends exclusively on CYP2D6 for deactivation and 
excretion. When inhibited by the SSRI, metroprolol concentration will peak in the 
cardiovascular tissue. Blood pressure will eventually drop to harmful levels, causing 
dizziness and loss of consciousness from hypotension
27
. 
 
1.4.3 CYP2B6 
Cytochrome P450 2B6 is a small, membrane bound enzyme found in the 
endoplasmic reticulum of liver cells, and composes less than 1% of the hepatic CYP450 
population
17
. Due to its comparatively meager stock, CYP2B6 was often considered to 
have an insignificant role in drug metabolism. However, recent studies have suggested 
that the enzyme is responsible for the activation of nevirapine and efavirenz, both non-
nucleoside reverse transcritptase inhibitors (NNRTIs) used in antiretroviral therapy for 
the treatment of HIV-1
28
. A listing of additional substrates and inhibitors of CYP2B6 can 
be found on Table 3. 
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Table 3. List of Common Medications and Inhibitors of CYP2B6. 
 
 
1.4.4 Non-Selective Cytochrome P450 Probes 
 
 Due to the broad substrate selectivity of multiple cytochrome P450 isoforms, it is 
often useful to probe for potential interactions using non-selective CYP450 substrates.  
Classic examples of this include ethoxycoumarin and ethoxyresorufin, which can be 
metabolized by multiple cytochrome P450 isoforms.  The use of these substrates for 
inhibition studies is very well-represented in the literature, and can lead to identification 
of potential drug interactions. Woodhouse et al used 7-ethoxycoumarin as a probe for 
monooxygenase activity in liver tissue with primary biliary cirrhosis, observing a 
decrease in xenobiotic metabolism in microsomes derived from liver in late stage 
cirrhosis
29
.  In another study, Pelkonen et al monitored the effect of cigarette smoking on 
the induction of cytochrome P450 by measuring 7-ethoxyresorufin O-deethylation 
activity
30
. In the current study, the substrate 7-methoxycoumarin was selected as a 
general probe for cytochrome P450 activity, and the relative contributions to its 
metabolism by different human isoforms were assessed. 
Drugs Metabolized by CYP2B6
28
 Known Inhibitors of CYP2B6
23
 
NNRTIs 
-efavirenz, nevirapone 
 
Chemotherapy Agents 
-cyclophosamide 
-N,N’,N”- triethylenephosphoramide 
 
Other Drugs 
-lidocaine, diazepam 
-triethylenethiophosphoramide 
(chemotherapeutic) 
 
-metryrapone (hypercortisolism treatment) 
-ticlopidine (antiplatelet) 
-orphendrine (antihistamine) 
14 
 
1.5.0 Herbal-Drug Interactions  
 As described previously, the non-selective nature of the cytochrome P450 
enzymes creates an environment in which multiple compounds can compete effectively 
for the active site of the enzyme. Natural products represent a rich source of diverse 
xenobiotic compounds with the potential to impede drug metabolism
31
. Due to the lack of 
rigid standards in the production of herbal and botanical supplements, it is common for a 
single herbal product to contain hundreds of unidentified organic compounds, whose 
effects on biochemical processes may not be fully investigated
16
.  
Recently, there has been a focus on investigating the effects of organic extracts 
from consumer-based herbal and botanical products on specific P450 isozymes. 
Furanocoumarins, such as bergamottin (BG) and 6’,7’-dihydroxybergamottin (DHB), are 
a particular class of botanical compounds proven to be strong inhibitors of intestinal 
CYP3A4, in vivo (Figure 5)
32
. Grapefruit juice, which contains a high concentration of 
these compounds, has been classified as a major constituent in CYP3A4 herbal-drug 
interactions, characteristic in cases when grapefruit juice is consumed simultaneously 
with medication during breakfast. As a result, the FDA requires cautionary labeling of 
several CYP3A4-mediating drugs (e.g. simvastatin, lovastatin, felodipine) to prevent 
adverse drug interactions when combined with grapefruit juice consumption
33
. An in 
vitro study suggests that BG and DHB are both potent irreversible inhibitors that act 
independently of substrate concentration
34
. 
15 
 
 
Figure 5. Structures of Bergamottin and 6’,7’-Dihydroxybergamottin. Both BG (a) 
and DHB (b) are natural constituents in grapefruit juice that lead to CYP3A4 
inhibition. 
 
 
1.5.1 Amazonian Acai Berry 
With these recent discoveries, this study will focus on the investigation of the 
inhibitory potential of the Amazonian acai berry (Euterpe oleracea) on select cytochrome 
P450 isozymes involved in drug metabolism. The berry is available in a variety of 
beverages and has become a popular dietary supplement, with claims of reducing LDL 
cholesterol levels and supplementing weight-loss
35
.  Despite these claims, the acai berry 
is not listed on the U.S. Food and Drug Administration Generally Recognized As Safe 
(GRAS) list, as studies into the bioactivity of acai berry constituents is very limited. 
Screening of the acai berry pulp and juice by the Cech group at UNCG has shown 
a strong presence of anthocyanin-class flavonoids, such as cyanidin-3-O-glucoside (C3G) 
and cyanidin-3-O-rutinoside (C3R). Pharmacokinetic analysis into the oral bioavailability 
16 
 
of acai juice show that plasma anthocyanin concentrations reach a maximum of 1.1-2.3 
ng/mL after consuming 18 fl. oz. in an average adult. These compounds have been 
implicated in the scavenging of free radicals, making acai berry a powerful antioxidant
36
. 
Additionally, these cyandins have been proven to be modest inhibitors of CYP3A4, with 
high IC50 values (80.2 µM for C3G and 96.1 µM for C3R)
37
. Despite these results, 
detailed studies aimed at the potential interaction of acai products with human drug-
metabolizing CYP450s have not been carried out. 
 
1.6.0 Bioassay-Guided Fractionation 
The primary strategy for this study involves the process of bioassay guided 
fractionation (BGF). The technique incorporates a bioactivity-directed approach in order 
to separate, isolate, and discover molecules that may have pharmacological or 
toxicological significance in the body. This method is particular useful in the evaluation 
of the pharmacognostic properties of natural products, which can contain an enormity of 
constituents
38
. 
BGF begins with an initial partitioning of a natural product into crude extracts. 
Each extract is assayed for interactions in a specific biochemical reaction. Extracts that 
demonstrate bioactivity are fractionated further, reducing the complexity of constituents 
in each newly generated fraction. The process repeats until individual bioactive 
molecules are isolated
39
. One potential drawback to this method involves the inability to 
identify bioactivity that occurs due to the cooperation of more than one compound. 
Fractionation could potentially separate these constituents into different extracts, 
rendering their synergistic bioactivity inoperative and unobservable
40
. 
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Bioassay guided fractionation has proven to be an essential tool in discovering 
many valuable compounds derived from botanical sources. In 1955, the National Cancer 
Institute (NCI) commissioned a program to screen more than 114,000 natural products
41
. 
In a landmark study at the Research Triangle Institute, extracts from endophytic fungi of 
the Pacific yew tree (Taxus brevifolia) were fractionated based on observed anti-leukemic 
activity. This led to the discovery of paclitaxel, a widely distributed chemotherapeutic 
agent
42
. In another study utilizing BGF, researchers uncovered an array of beneficial 
compounds isolated from the unripe South American avocado (Persea americana). 
Fractionation revealed several long chain triols that demonstrated significant cytotoxic 
selectivity of the PC-3 human prostate carcinoma cell line. The same study also found 
that one of these compounds exhibited potent lethality towards the larvae of the yellow 
fever mosquito (Aedes aegypti), implying that it could serve as a natural insecticide
43
.  
This study utilizes BGF in a collaborative effort between several research groups 
at UNCG that focuses on characterization and identification of bioactive constituents in 
the acai berry. Freeze-dried acai berry powder from Optimally Organic, Inc. was 
fractionated into aliquots that were tested for inhibition in cytochrome P450 assays. 
Fractions that exhibited high inhibitory activity can then be further partitioned by polarity 
to reduce their complexity. This process continues until the fractions contain single 
compounds. This strategy utilizes the complimentary expertise of the Raner and Oberlies 
research groups at UNCG. Robin Tate-Uhl and Tyler Graf, from Dr. Oberlies’ laboratory, 
carried out the fractionation and partitioning of acai berry extracts.  
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1.7.0 Objective Statement 
The goal of this study is to investigate the potential inhibition of several 
cytochrome P450-mediated reactions by the Amazonian acai berry (Euterpe olecera). To 
this date, there have been no published data showing acai berry inhibition of CYP450. 
This study is being carried out parallel with another at UNCG in which other isoforms of 
toxicological significance are the main focus, where preliminary studies have 
demonstrated inhibitory activity by acai berry extracts toward both CYP 2E1 and 2A6. 
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CHAPTER II 
 
EXPERIMENTAL 
2.1.0 Preparation of Reagents and Stock Solutions 
 
 
2.1.1 Potassium Phosphate Buffer 
A 1 M stock of potassium phosphate buffer was prepared by combining 
monobasic potassium phosphate and dibasic potassium phosphate, both provided by 
Carolina Biological Supply Company. The pH of the buffer was adjusted to 7.4 after 
combining the phosphate solutions. This buffer was used in all CYP450 assays described 
below as a 10x stock. 
 
2.1.2 NADPH 
Nicotinamide adenine dinucleotide phosphate (NADPH), Research Products 
International (RPI), was dissolved in deionized water and partitioned into 10 mM stock 
solution aliquots. These aliquots were stored at -80
o
C until used in CYP450 assays. 
 
2.1.3 Rat Liver Microsomes  
Microsomal extractions from rat livers served as a model for hepatic cytochrome 
P450 enzymes found in humans 15.02 g of frozen rat livers, Pel-Freez Biological in 
Rogers, AK, were thawed and washed in 60 mL of a buffer consisting of 100 mM 
potassium phosphate buffer (7.4), 20 % glycerol, 3.3 mM MgCl2, and 0.1 mM EDTA. 
The tissue and buffer solution were homogenized in a commercial blender in 20 second  
20 
 
bursts. The slurry was centrifuged at 5,000 rpm for 10 minutes. The supernatant was 
decanted and centrifuged at 25,000 x g for 1 hour. The supernatant was discarded, and the 
pellet was resuspended and homogenized in 20 mL of the buffer, and stored at -80
o
C. A 
Bradford assay was carried out with bovine serum albumin as the standard for generating 
a calibration curve in order to find the protein concentration of the rat liver microsome 
stock.  The approximate protein concentration was determined to be 15.3 mg/mL. 
 
2.1.4 Human Liver S9 Fractions  
Microsomes obtained from the S9 fraction of human liver homogenate were 
purchased by Molecular Toxicology, Inc., Asheville, NC, and were stored in 60 µL 
aliquots at -80
o
C. These microsomes were at a reported concentration of 23.3 mg/mL 
total protein. 
 
2.1.5 Substrate Stock Solutions 
Erythromycin and dextromethorphan were purchased from Sigma, while 7-
methoxycoumarin was purchased from Acros Organics. Erythromycin (200 µM), 
dextromethorphan (200 µM), and 7-methoxycoumarin (1 mM) were dissolved in 10 % 
methanol, due to their low solubility in H2O, and stored at room temperature. 
 
2.1.6 Nash Reagent 
Nash Reagent was used to quantify the amount of formaldehyde produced in the 
CYP3A4 and 2D6 reactions. It was prepared using 15 g of ammonium acetate, 200 µL of 
penta-2,4-dione, and 400 µL glacial acetic acid in a total volume of 50 mL. The solution 
was stored in a 4
o
C refrigerator and kept in low light conditions. 
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2.1.7 Acai Berry Fractions 
The acai berry fractions were prepared by collaborators in the Dr. Oberlies 
research group. Upon arrival, the fractions were divided into aliquots 25-20µg and stored 
in the refrigerator at 4
o
C. For study into bioassay inhibition, the fractions were diluted to 
produce stock solutions between 250-2000 µg/mL. Aqueous and butanol extracted 
fractions were dissolved in H2O, while chloroform and hexane extracted fractions were 
dissolved in 10 % methanol. 
 
2.2.0 Cytochrome P450 Assays 
An in vitro reaction assay to test the activity of each CYP450 isoform was first 
developed before testing the acai berry extracts for inhibition. The approach to develop 
these assays followed similar protocol to past CYP450 inhibition studies, which include 
the incubation of purified hepatic microsomes, substrate, NADPH, and buffer (7.4) at 
37
o
C to initiate the monooxygenase reaction. Measuring product formation with variable 
substrate, microsome, and reaction time suggested that the reactions were linear for up to 
an hour and obeyed a simple Michaelis-Menten kinetic model. 
 
2.2.1 Nash Reagent Assay  
The Nash assay, a reliable method for monitoring reactions that produce 
formaldehyde as a product, has been used in a number of recent CYP450 studies
44,45,46
. 
For this study, the Nash assay was utilized to measure activity of the CYP3A4 and 2D6-
model assays. This method involves the reaction of 2,4-pentanedione and ammonium 
acetate with formaldehyde to form 3,5-diacetyl-2,6-dihydolutidine (Figure 6), a yellow 
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product that can be measured using UV-Vis spectrophotometry at an absorbance 
wavelength of 412 nm
47
. 
 
 
Figure 6. Reaction of the Nash Reagent Assay. Active components in the Nash 
reagent, 2,4-pentanedione and ammonium acetate, react with formaldehyde to 
produce a pale yellow chromaphore. 
 
 
2.2.2 CYP3A4 Model Assay  
Rat liver microsomes were used as a source of cytochrome P450 enzymes in this 
assay. The rat CYP3A2 isoform has been implicated as a model homologue for the 
human-expressed CYP3A4 enzyme
48,49,50
. Additionally, the CYP3A2 isoform has been 
shown to metabolize several prominent CYP3A4 substrates, including testosterone
51
, 
erythromycin
49
, and midazolam
52
. For this study, the rat CYP3A2 isoform was 
determined to serves as an adequate model for the human CYP3A4 homologue. 
Erythromycin, an antibiotic macrolide, is a commonly used substrate to probe 
cytochrome P450 3A2 activity. Given its highly selective nature, this compound was 
elected as the substrate for monitoring CYP3A2 activity. Erythromycin undergoes an N-
demethylation to produce a demethylated erythromycin-derivative and formaldehyde, as 
seen in Figure 7
49
.  
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Figure 7. Reaction for Erythromycin N-Demethylation with CYP3A2/3A4.  In this 
reaction, the enzyme utilizes NADPH and O2 to demethylate the amine group. The 
formaldehyde product can be quantitated using colorimetric detection.      
The erythromycin N-demethylation assay was carried out in 1.5 mL centrifuge 
tubes using rat liver microsomes (1.1 mg/mL), 10 μM erythromycin, 0.1 M potassium 
phosphate buffer (7.4), 5 mM MgCl2, and 1 mM NADPH. The reactions were carried out 
in a final volume of 200 μL. Reactions were initiated with the addition of NADPH, and 
were incubated at 37
o
C for 15 minutes. Reactions were terminated with 100 μL of 10% 
trichloroacetic acid. Samples were chilled in an ice bath for 10 minutes, and then 
centrifuged at 15,800 g for 10 minutes. Supernatant for each sample was extracted and 
placed into new centrifuge tubes with 300 μL of Nash reagent. Samples were then 
incubated at 50
o
C in low light condition for 30 minutes. Samples were immediately 
placed into a UV-Vis spectrophotometer (Varian 50 Bio UV-Visible Spectrophotometer) 
and absorbance was measured at 412 nm. For each analysis, the UV-Vis detector was 
zeroed via normalization with a ‘blank’ consisting of all reaction components with the 
enzyme quenched prior to addition of NADPH to prevent enzyme activity.  
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2.2.3 CYP2D6 Model Assay  
Given the use of rat liver micromsomes in this assay, it’s important to mention 
that the rat CYP2D1 isoform is a confirmed homologue of the human CYP2D6
53,54
. 
Dextromethorphan, an antitussive found in cough syrup, has been shown to be 
metabolized by both the CYP2D1
55
 and 2D6
56
 isoforms. CYP2D1, serving as a model for 
CYP2D6 in this study, initiates an O-demethylation reaction with the substrate, 
producing dextrorphan and formaldehyde (Figure 8).  
 
  
Figure 8. Reaction of Dextromethorphan O-Demethylation with CYP2D1/2D6. This 
enzyme uses NADPH and O2 for the demethylation of the ester substituent on 
dextromethorphan. The formaldehyde product formation can be quantitated using 
colorimetric analysis. 
 The dextromethorphan O-demethylation assay was set up in 1.5 mL centrifuge 
tubes using rat liver microsomes (1.1 µg/mL), 10 μM dextromethorphan, 0.1 M 
potassium phosphate buffer (7.4), 5 mM MgCl2, and 1 mM NADPH. The samples were 
diluted in H2O to a final volume of 200 μL. Reactions were initiated by the addition of 
NADPH, and were incubated at 37
o
C for 30 minutes. Reactions were terminated with 100 
μL of 10% trichloroacetic acid. Samples were chilled in an ice bath for 10 minutes, and 
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then centrifuged for 10 minutes at 15,800 g. The supernatant for each sample was 
extracted and placed into new centrifuge tubes with 300 μL of Nash reagent. Samples 
were then incubated at 50
o
C in low light condition for 30 minutes. Samples were 
immediately placed into a UV-Vis spectrophotometer and absorbance was measured at 
412 nm. For each analysis, the UV-Vis detector was zeroed via normalization with a 
‘blank’ consisting of all reaction components with the enzyme quenched prior to 
incubation to prevent enzyme activity. 
 
2.2.4 7-Methoxycoumarin O-Demethylation (MCOD) Assay  
For this assay, human liver CYP450 derived from hepatic S9 fractions were 
utilized to probe additional cytochrome P450 isozymes. 7-methoxycoumarin was selected 
as an analytical substrate for probing human CYP450 metabolism due to its fluorogenic 
properties
57
. The compound is a 7-alkyl derivative of coumarin, a flavenoid used as a 
synthetic precursor for several anticoagulants
58
. The methoxy group is hydroxylated by 
cytochrome P450, leading to demethylation and subsequent formation of 7-
hydroxycoumarin
57
, as seen in Figure 9. 
 
 
 
Figure 9. Reaction for 7-Methoxycoumarin O-Demethylation Reaction with Human 
Liver Microsomes. The product, 7-hydroxycoumarin, is a fluorescent biomarker. 
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At the beginning of this study, it was assumed that 7-methoxycoumarin O-
demethytlation was mediated, in part, by the CYP2B6 due to implications from various 
studies. Rat CYP2B-class homologues were found to be major metabolizers of 7-
methoxycoumarin
59
, while human CYP2B6 found to mediate the hydroxylation of 
several 7-alkycoumarin derivatives
60
. The current study supports this assumption, and has 
identified additional human isozymes contributing to 7-methoxycoumarin O-
demethylation. The literature indicates that phenobarbital-induced cytochrome P450s, 
which can include a wide range of isozymes from the 2A, 2B, and 2C families
61
, have 
been shown to be predominate metabolizers of the compound, demonstrating an 8-fold 
increase in product formation versus non-induced microsomes
59
.  Additionally, studies 
have utilized 7-methoxycoumarin as a selective probe for CYP1A2
62
 and CYP2A6
63
 
activity. Our own data and studies indicate 7-methoxycoumarin is a good general probe 
for CYP450 activity. 
 The MCOD assay was set up in 1.5 mL centrifuge tubes using S9 fraction of 
human liver microsomes (0.35 mg/mL), 50 μM 7-methoxycoumarin, 0.1 M potassium 
phosphate buffer (7.4), and 1 mM NADPH. The samples were diluted in H2O to a final 
volume of 200 μL. Reactions were initiated with the addition of NADPH, and were 
incubated at 37
o
C for 45 minutes. Reactions were terminated with 50 μL of 3% formic 
acid, then chilled in an ice bath for 10 minutes. 
 Back extraction was necessary to isolate the organic product prior to fluorescence 
detection due to the potential interference from NADPH. Following quenching, 400 µL 
of chloroform were added to each sample. Each tube was vortexed for 30 seconds, then 
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centrifuged at 14,000 rpm for 5 minutes. 350 µL of the bottom layer organic phase was 
extracted from each sample and placed in 1000 µL of 30 mM sodium borate (pH 9.2). 
The samples were vortexed and centrifuged under the same conditions.  1000 µL of the 
top layer was extracted into a cuvette for fluorescence analysis. The detector in the 
Varian Cary Eclipse Fluorescence Spectrophotometer was set to excitation wavelength of 
360 nm and emission wavelength of 450 nm. For each analysis, the fluorescence baseline 
was normalized with a ‘blank’ consisting of all reaction components with the enzyme 
quenched prior to incubation to prevent enzyme activity. 
 In the later stages of the study, HPLC was utilized to measure the formation of 7-
hydroxcoumarin without using the back extraction method. 50 µL of each sample was 
injected into a Waters XBridge C18 column (4.6 x 150 mm) using a model LC-20AT 
system (Shimadzu Corp.). An isocratic mobile phase of 20% acetonitrile (with .1% 
trifluoroacetic acid) and 80% nanopure water (with .1% TFA) was pumped through the 
system at a rate of 0.600 mL/min. 7-hydroxycoumarin was measured for UV absorbance 
at 320 nm at a retention time of approximately 6.4 minutes
64
. 
 
2.3.0 Initial Partition of Acai Berry Powder 
In the initial fractionation of the acai berry powder, solvent partitioning was used 
to create four crude acai berry fractions. The partitioning process, summarized in Scheme 
1, involved dissolving the acai berry powder into a 10:1:9 hexane:H2O:methanol mixture. 
The organic phase was extracted from the mixture using a seperatory funnel, isolating 
highly lipophilic constituents, such as fatty acids and oils. This hexane solution was 
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aliquoted and dried, producing samples labeled Hexane. The remaining aqueous 
methanol was mixed with chloroform, producing a 4:1:5 CHCl3:MeOH:H2O mixture. 
The organic phase was separated and divided into dried aliquots, producing samples 
labeled Chloroform. The remaining mixture was mixed with butanol to create a 1:1 
BuOH:H2O mixture. Both the butanol and aqueous layers were separated, aliquoted, and 
dried to produce the last two samples, labeled Butanol and Aqueous.  
 
  
 
Scheme 1. Generation of Crude Acai Berry Fractions.  
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2.3.1 Generation of Acai Berry Fractions  
Scheme 2 is a diagram of the entire fractionation process throughout the course of 
this study. Starting with the freeze dried acai berry powder, four crude fractions were 
generated, as described in the above section. The subsequent fractions were generated 
using various chromatographic methods by our collaborators in the Oberlies lab 
(University of North Carolina at Greensboro). The Chloroform sample was fractionated 
with silica-column flash chromatography (RF CombiFlash) with C6H14:CHCl3:MeOH 
solvent gradient, generating the 34 series. The 34-08 sample was fractionated with the 
same instrument, instead using C6H14:acetone solvent gradient and producing the 38 
series of fractions. The 38-02 sample was subsequently fractionated into the 62 series, 
using a diol column with C6H14:ethyl acetate:MeOH gradient. The 62-02 and 62-03 
samples were selected to be fractionated into the 78 and 82 series, respectively, as shown 
in the diagram below. For both fractionations, reverse phase HPLC was used with 
ACN:H2O solvent gradient. 
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Scheme 2. Summary of Inhibition-Directed Fractionation of Acai Berry Powder. 
This pathway is based on observed inhibition of the MOCD activity in human liver 
microsomes. 
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CHAPTER III 
 
RESULTS AND DISCUSSION 
3.1.0 Bioassay Development  
 While developing the bioassays to measure the activities of each CYP450 
isoform, several components of each reaction were tested at variable amounts in order to 
optimize conditions for the assay. This process included examining the effects of varying 
enzyme concentration, incubation time, and substrate concentration. Product formation 
should be linear with time and increase with enzyme concentration in a linear fashion. 
With varying substrate concentration, the reaction rate should follow a non-linear 
function in association with Michaelis-Menten kinetics. These steps were taken to ensure 
that each CYP450 reaction demonstrated enzymatic behavior, as well as optimizing 
various parameters for each assay before beginning the acai berry inhibition screening. 
 
3.1.1 CYP3A4 Model Assay 
 The erythromycin N-demethylation reaction was first tested with variable enzyme 
concentrations. The goal of this experiment was to establish linearity between reaction 
rate and enzyme concentration, as well as selecting an appropriate volume of rat liver 
microsomes to use in the subsequent CYP3A4 assays. These reactions were carried out in 
similar conditions described in the previous chapter. Figure 10 illustrates the results of 
these reactions, which were tested with 15-45 µL of rat liver microsomes. A linear 
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increase in activity was observed in correlation with the increase in microsome 
concentration. Here, the activity was represented in using arbitrary activity units per 30 
minute reaction. For optimization, it was decided that 15 µL of rat liver microsomes were 
to be used in subsequent CYP3A4 reactions. The volume was selected due to the 
sufficient measurement of activity at a minimal volume, in order to conserve the 
microsomal stock solution. 
 
Figure 10. Results for Variation of Microsomal Volume in the CYP3A4 Model 
Assay. 
Additionally, the CYP3A4 reaction was tested with varying reaction times. This 
involved running reactions under similar conditions with incubation times that varied 
from 5-20 minutes, the results of which can be seen in Figure 11. Once again, a linear 
increase in product formation in relation to the increase in reaction time was observed, 
also indicating that reaction times of 20 or more minutes would be appropriate. For the 
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acai berry screening, an incubation time of 30 minutes was decided upon for the CYP3A4 
assay. 
 
Figure 11. Results for Variation of Incubation Time in the CYP3A4 Model Assay 
The final step in developing the CYP3A4 assay prior to the inhibition studies 
involved testing varying substrate (erythromycin) concentrations. The resulting data 
should demonstrate a non-linear relationship between reaction rate and substrate 
concentration, resulting in a rectangular hyperbolic curve indicative of Michaelis-Menten 
kinetics. The Km value can be extracted from the plot, giving a relatively ideal substrate 
concentration to use in the acai berry inhibition study. At such a concentration, 50% of 
the enzyme is bound to the substrate, creating a reaction environment in which inhibition 
can be readily observed. Figure 12 shows the results of testing the CYP3A4 reaction with 
0.1 – 25 µM of erythromycin. The resulting Km value of 4.9 µM and Vmax value of 2.6 x 
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10
-2 activity units/mg of protein/minute were obtained from the data. An erythromycin 
concentration of 10 µM was adopted from this Km value and used in the acai berry 
inhibition screening. 
 
Figure 12. Michaelis-Menten Curve of CYP3A4 Model Erythromycin N-
Demethylase. 
3.1.2 CYP2D6 Model Assay 
 The CYP2D6 dextromethorphan O-demethylation reaction was first tested with 
variable enzyme concentrations and total formaldehyde produced was measured by the 
Nash assay. The goal of this experiment was to establish linearity between reaction rate 
and enzyme concentration, as well as selecting an appropriate volume of rat liver 
microsomes to use in the subsequent CYP2D6 assays. These reactions were carried out in 
similar conditions described in the Experimental section. Figure 13 illustrates the results 
of these reactions, which were tested with 15-45 µL of rat liver microsomes. A linear 
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increase in activity, measured in activity values from the Nash Assay, can be observed in 
correlation with the increase in microsome concentration. The volume of 15 µL, in order 
to conserve the rat liver microsome stock solution while still giving adequate activity, 
was chosen for subsequent CYP2D6 reactions. 
 
Figure 13. Results for Variation of Microsomal Volume in the CYP2D6 Model 
Assay. 
Additionally, the CYP2D6 reaction was tested with varying reaction times to 
ensure linearity over the entire course of the reaction. This involved carrying out 
reactions with 15 µL of microsomes and incubation times that varied from 15-45 
minutes, the results of which can be seen in Figure 14. The data indicates a linear 
increase in production formation in relation to the increase in reaction time. For the acai 
berry screening, an incubation time of 30 minutes was decided upon for the CYP2D6 
assay. 
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Figure 14. Results for Variation of Incubation Time in the CYP2D6 Model Assay. 
Examining the relationship between substrate (dextromethorphan) concentrations 
and reaction activity was the last step in optimizing the CYP2D6 assay for inhibition 
study.  Dextromethorphan was varied at a range of 0.1 – 50 µM; the results of which are 
shown in Figure 15. As demonstrated in the graph, activity follows a non-linear 
relationship indicative of Michaelis-Menten kinetics. Here, the Vmax of the reaction was 
determined to be 3.2 x 10
-2
 activity units/mg of protein/minute. A value of 9.2 µM was 
determined for the Km of the reaction, and a dextromethorphan concentration of 10 µM 
was determined to be appropriate for use in the acai berry inhibition screening study. 
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Figure 15. Michaelis-Menten Curve of CYP2D6 Model Dextromethorphan O-
Demethylation. 
3.1.3 MCOD Assay 
Optimization of 7-methoxycoumarin O-demethylase involved testing the assay 
with variable enzyme concentrations. A linear relationship should be observed between 
enzyme concentration and product formation in the MCOD reaction. As illustrated in 
Figure 16, the assay was tested with human S9 fractions at a range of volumes between 1-
5 µL, demonstrating linearity in the reaction. For optimization, 3 µL of S9 fraction 
microsomes were selected based on the adequate amount of observed fluorescence 
activity, and subsequently used in future MCOD experiments. Also, this small volume 
was selected to maximize the number of reactions that could be carried out from a single 
aliquot of human S9 fraction stock solution. 
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Figure 16. Results for Variation of Microsomal Volume in the MCOD Assay. 
Additionally, the MCOD assay was tested with varying reaction times. These 
reactions were carried out with 3 µL of S9 fraction microsomes and incubation times that 
varied from 15-60 minutes. In Figure 17, the results of this experiment show that there is 
a linear increase in enzyme activity in relation to the increase in reaction time. Based on 
the sufficient amount of activity observed, a reaction incubation time of 45 minutes was 
selected as the optimal time for MCOD assays during the inhibition studies. 
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Figure 17. Results for Variation of Incubation Time in the MCOD Assay. 
The final step in optimizing the MCOD assay involved examining the relationship 
between varying concentrations of the substrate (7-methoxycoumarin) and reaction rate. 
Figure 18 shows the results of this experiment using 25 – 600 µM 7-methoxycoumarin. 
The results indicate a non-linear relationship indicative of Michaelis-Menten kinetics, 
with a Km value of 53 µM and Vmax of 1.2 x 10
2
 activity units/mg of protein/minute in the 
reaction. Based on the Km value, a substrate concentration of 50 µM was selected to be 
used during the inhibition studies on MCOD. 
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Figure 18. Michaelis-Menten Curve of the 7-Methoxycoumarin O-Demethylation 
Reaction. 
 As discussed previously, multiple cytochrome P450 isoforms are responsible for 
the 7-methoxycoumarin reaction. The initial assumption was CYP2B6 was a major 
contributor, but that CYP1A2
62
and 2A6
63
 could play a role in the metabolism of 7-MC  
as well. An additional objective was to confirm involvement of specific isoforms using 
selectively-expressed cytochrome P450 supersomes. Each of the available supersomes 
(CYP2A6, 1A1, 1A2, 2E1, and 2C8) was tested in control reactions with 50 µM 7-
methoxycoumarin, 0.1 M phosphate buffer, 1.0 mM NADPH, and 3 µL of supersomes. 
The results, shown in Figure 19, displayed observed fluorescence activity indicative of 7-
hydroxycoumarin formation. From these results, it can be implied that in addition to 2B6. 
CYP2A6, 1A2, and 2E1 demonstrate prominent 7-methoxycoumarin O-demethylation 
activity. 
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Figure 19. Results for Screening of Several Cytochrome P450 Isoform-Specific 
Supersomes for MCOD Activity.  
3.2.0 Inhibition-Directed Fractionation of Acai Berry  
 The initial fractionation, summarized in Scheme 1, produced four crude samples 
for bioactivity testing. These initial fractions were screened for inhibition in the rat 
cytochrome P450 3A4, 2D6, and human MCOD assays, as described in the Materials and 
Methods section. The results were as follows:  
3.2.1 Crude Acai Berry Fractions 
 The initial acai berry fractions were tested for bioactivity with the CYP3A4 assay. 
The objective of this experiment was to observe reduction in CYP3A4 activity from each 
crude fraction in the reaction mixture. Each assay was performed with 10 µM substrate, 
1.1 mg/mL rat liver microsomes, and incubated for 30 minutes, as established in section 
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3.1.1. The fractions were tested individually at a final reaction concentration of 200 
µg/mL. This high concentration was used in order to catch high potency, low abundance 
inhibitors that may be present. The results of this experiment, as seen in Figure 21, are 
presented as percentage of activity in the acai-treated reactions versus the control. The 
aqueous fraction showed 100.1 ± 3.9 % activity, the butanol fraction showed 96.0 ± 1.2 
%, the chloroform fraction showed 111.0 ± 0.5 %, and the hexane fraction showed 107.5 
± 0.5 activity. No remarkable reduction in CYP3A4 activity was observed for any of 
these crude fractions, and further fractionation based on CYP3A4 inhibition was not 
pursued. Such results indicate that multiple extracts of the acai berry do not interfere with 
CYP3A4 metabolism. In particular, the butanol fraction was expected to be rich in 
anthocyanins, a class of pigmented flavonoids that have been shown to be only weak 
inhibitors of human CYP3A4
37
,  which is consistent with the lack of inhibition observed 
in the current study using the butanol extract. While there still may be the possibility that 
a CYP3A4 inhibitor could be present in other extracts, it is doubtful they pose any 
pharmacokinetic significance due to their extremely low concentrations. 
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Figure 20. Results for the Screening of the Crude Fractions for CYP3A4 Inhibition. 
 The crude acai berry fractions were tested with the CYP2D6 assay. Similar to the 
previous experiment, the goal of this experiment was to determine bioactivity of each 
initial fraction by observing loss of CYP2D6 activity.  The assays were carried out under 
conditions described in section 3.2.2, with 10 µM substrate, 1.1 mg/mL rat liver 
microsomes, and incubated for 30 minutes. The results of these assays, as seen in Figure 
21, are reported as percentage of activity in the reactions containing acai fraction versus 
the control. The aqueous fraction showed a 96.7 ± 0.6 % activity; butanol fraction 
showed 79.7 ± 1.4 %; chloroform fraction showed 110.3 ± 1.9 %; hexane fraction 
showed 104.9 ± 0.3 % activity. Although the anthocyanin-rich butanol fraction did show 
modest inhibition, these compounds are classified as weak inhibitors of CYP2D6 as 
well
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. Given this knowledge of CYP2D6, along with the lack of inhibition observed at 
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200 g/mL, it is unlikely that there is any physiologically significant inhibition of 
CYP2D6 by acai products.  Thus for this assay, no further fractionation was carried out. 
 
Figure 21. Results for the Screening of the Crude Fractions for CYP2D6 Inhibition.  
 The crude acai fractions were next tested for inhibition of 7-methoxycoumarin O-
demethylation activity. Once again, each crude fraction was screened individually at a 
final reaction concentration of 200 µg/mL. For this experiment, reactions were carried 
out under optimal conditions established in section 3.1.3, with 50 µM substrate, 0.35 
mg/mL S9 microsomes, and incubated for 45 minutes. The results of these assays, as seen 
in Figure 22, are presented as percentage of activity in the presence of the acai fractions 
relative to the control. Once again, for the purpose of clarification, “active fractions” are 
defined as those that result in a substantial reduction in MCOD activity. Reactions carried 
out in the presence of 200 µg/mL of the dried aqueous extract showed 80.0 ± 5.0 % 
activity, while the butanol extract yielded 83.7 ± 1.9 % activity. The chloroform extract, 
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on the other hand, reduced the activity of MCOD to 5.3 ± 0.3 % of the control, while the 
hexane extract resulted in a more modest reduction to 43.0 ± 8.4 % activity. Since the 
chloroform extract showed the most remarkable inhibition of MCOD activity, it was 
selected for further fractionation. The hexane extract, although somewhat inhibitory, was 
not further fractionated. 
 
Figure 22. Results from the Screening of the Crude Fractions for MCOD Inhibition. 
3.2.2 Generation 1 (34 Series) 
 Fractionation of the chloroform extract resulted in the creation of ten samples 
designated as the 34 series, as illustrated in Scheme 3. These fractions were tested in the 
MCOD reaction along with the parent chloroform fraction. The concentration of each 
extract in these reactions was lowered to 50 µg/mL in order to distinguish which fractions 
contained the more potent inhibitors. The results of this screening are shown in Figure 23, 
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and are reported as percentage activity in the presence of extract, relative to controls. 
Reactions containing the parent fraction showed 24.1 ± 6.4 % activity, 34-01 showed 
81.8 ± 7.9 % activity, 34-02 showed 65.4 ± 5.0 % activity, 34-03 showed 79.1 ± 5.2 % 
activity, 34-04 showed 84.8 ± 6.5 % activity, 34-05 showed 60.6 ± 0.5 % activity, 34-06 
showed 59.7 ± 6.4 % activity, 34-07 showed 40.3 ± 3.3 % activity, 34-08 showed 35.1 ± 
5.1 % activity, 34-09 showed 59.7 ± 5.6 % activity, and 34-10 showed 49.3 ± 1.9 % 
activity. It should be noted that there was an expectation that many fractions would show 
some degree inhibition. CYP450 enzymes have broad substrate selectivity, which is an 
important property in relation to its function of detoxification. The complexity of natural 
product extracts, including the acai berry, leads to a high potential for inhibition of 
CYP450 enzymes by multiple components. The scope of this portion of the study is to 
identify those fractions which have the strongest potential for inhibition, particularly 
when compared to their parent fraction. For this experiment, 34-08 fraction was chosen 
for further fractionation due to its pronounced inhibition of MCOD. The other fractions 
were not further investigated.  
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Scheme 3. Generation of the 34 Series of Fractions. 
 
Figure 23. Results for the Screening of the 34 Series Fractions. These were screened 
along with the parent chloroform fraction at 50 µg/mL reaction concentration. 
 
0
10
20
30
40
50
60
70
80
90
100
CHCl3 34-01 34-02 34-03 34-04 34-05 34-06 34-07 34-08 34-09 34-10
%
 A
ct
iv
it
y
 v
s 
C
o
n
tr
o
l 
Acai Fraction (50 µg/mL) 
48 
 
3.2.3 Generation 2 (38 Series) 
The 34-08 fraction was partitioned into eight samples, the 38 series, as seen in 
Scheme 4. In this experiment, each of these eight samples, along with the parent fraction, 
were tested in the 7-methoxycouamrin O-demethylation reaction at a concentration of 50 
µg/mL. As before, the results of this screening are reported as percentage of activity 
relative to the control reaction (Figure 24). At this dose, the parent 34-08 sample reduced 
activity to 28.8 ± 6.1 %, 38-01 reduced activity to 36.1 ± 2.3 %, 38-02 resulted in 26.4 ± 
3.0 % activity, 38-03 resulted in 44.5 ± 5.1 % activity, 38-04 resulted in 66.7 ± 14.2 % 
activity, 38-05 resulted in 49.9 ± 7.9 % activity, 38-06 resulted in 24.8 ± 9.7 % activity, 
38-07 resulted in 30.2 ± 4.8 % activity, and 38-08 resulted in the most substantial 
reduction in activity with only 11.3 ± 1.2 % remaining. Once again, a significant number 
of fractions showed varying degrees of low to moderate inhibition. From this experiment, 
38-02, 38-06, and 38-08 showed remarkable inhibition of the MCOD reaction. Given the 
multitude of bioactive fractions, the next generation bifurcated into two offspring series. 
38-02 was partitioned into five fractions, referred to as the 62 series. 38-06 and 38-08, 
due to limited sample availability, were pooled together with 38-07 and subsequently 
partitioned into the 86 series, producing seven fractions. 
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Scheme 4. Generation of the 38 Series of Fractions 
 
Figure 24. Results for the Screening of the 38 Series Fractions. These fractions were 
screened along with the parent 34-08 fraction at 50 µg/mL reaction concentration. 
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3.2.4 Generation 3 (62 and 86 Series) 
 38-02 was partitioned into five fractions designated as the 62 series, as seen in 
Scheme 5. These fractions were tested in the MCOD assay for inhibition along with the 
parent fraction. The fraction concentration in the reactions was lowered to 25 µg/mL in 
order to distinguish which fractions contained the more potent inhibitors. The results, 
shown in Figure 25, are once again reported as percent activity relative to the control. 
The parent fraction reported activity at 58.1 ± 1.7 %, 62-01 at 73.7 ± 2.2 % activity, 62-
02 at 53.9 ± 8.9 % activity, 62-03 at 51.3 ± 9.5 % activity, 62-04 at 61.9 ± 10.8 % 
activity, and 62-05 at 100.9 ± 12.3 % activity. The 62-02 fraction was selected to be 
furthered studied and fractionated into the 78 series, along with the 62-03 fraction, which 
was fractionated into the 82 series. The other fractions were not further investigated.  
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Scheme 5. Generation of the 62 Series of Fractions. 
 
Figure 25. Results for the Screening of the 62 Series Fractions. These fractions were 
tested along with the parent 38-02 fraction at 25 µg/mL reaction concentration 
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As previously stated, the 86 series contains seven fractions, whose starting 
material (defined as 86-SM) are the amalgamation of 38-06, 38-07, and 38-08 fractions 
from the previous generation. Each fraction, along with starting material, was tested in 
the MCOD reaction at 50 µg/mL. The results of this screening are reported in Figure 26, 
showing the percentage of observed activity in acai-treated reactions relative to control. 
86-SM showed 48.5 ± 7.6% activity, 86-01 showed 90.8 ± 9.6% activity, 86-02 showed 
65.1 ± 9.3% activity, 86-03 showed 55.8 ± 8.9% activity, 86-04 showed 54.2 ± 6.8% 
activity, 86-05 showed 47.6 ± 5.3% activity, 86-06 showed 42.1 ± 5.2% activity, and 86-
07 showed 50.0 ± 11.1 % activity. Several fractions, including 86-05, 06, and 07 showed 
remarkable inhibition when compared to the starting material. However, further 
investigation into the composition of these fractions have yet to be pursued at this time. 
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Scheme 6. Generation of the 86 Series of Fractions. 
 
Figure 26. Results for the Screening of the 86 Series Fractions. The starting 
material, 86-SM, is comprised of the 38-06, 38-07, and 38-08 pooled together. These 
fractions were screened at a reaction concentration of 50 µg/mL. 
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3.2.5 Generation 4 (78 and 82 Series) 
 The 62-02 fraction was investigated first, and resulted in the creation of eight 
fractions designated as the 78 series. These fractions were tested in the MCOD reaction, 
along with the parent fraction, at 25 µg/mL. The results of this screening are shown in 
Figure 27, and are reported as percentage of activity in the acai-treated reactions versus 
the control. The parent fraction (62-02) produced activity of 28.3 ± 13.1 %, 78-A gave 
64.0 ± 2.1 % activity, 78-B gave 90.3 ± 20.5 % activity, 78-C gave 50.8 ± 4.3 % activity, 
78-D gave 25.8 ± 3.8 % activity, 78-E gave 60.1 ± 7.7 % activity, 78-F gave 68.6 ± 4.7 % 
activity, 78-G gave 42.5 ± 7.8 % activity, and 78-H gave 52.7 ± 11.6 % activity. The 78-
D fraction, showing 74.2 % inhibition of 7-methoxycoumarin metabolism, was further 
investigated in order to determine its inhibition constant (Ki) and mode of inhibition. 
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Scheme 7. Generation of the 78 Series of Fractions. 
 
Figure 27. Results for the Screening of the 78 Series Fractions. These fractions were 
tested along with the parent 62-02 fraction at 25 µg/mL reaction concentration. 
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The last series of fractionations was performed on 62-03, and resulted in the 
creation of seven fractions designated as the 82 series. These fractions were tested in the 
MCOD reaction, along with the parent fraction, at 25 µg/mL. The results of this 
screening are shown in Figure 28, and are reported as percentage of activity in the acai-
treated reactions versus the control. The parent fraction (62-03) reported activity of 23.3 
± 6.1 %, 82-A reported 47.0 ± 0.7 % activity, 82-B reported 10.8 ± 3.9 % activity, 82-C 
reported 11.7 ± 3.4 % activity, 82-D reported 13.6 ± 7.3 % activity, 82-E reported 43.9 ± 
7.3 % activity, 82-F reported 23.1 ± 3.6 % activity, an 82-G reported 21.4 ± 0.4 % 
activity. Based on this analysis, the 82-B, 82-C, and 82-D fractions were determined to be 
the most potent, due to their inhibition relative to the starting material (62-03). Both 82-C 
and 82-D underwent further analysis in order to characterize their inhibition type and 
determine their Ki value. Supply of the 82-B fraction had been diminished at this time in 
the study, and was unable to be analyzed. 
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Scheme 8. Generation of the 82 Series of Fractions. 
 
Figure 28. Results for the Screening of the 82 Series Fractions. This series, along 
with the parent 62-03 fraction, was tested at 25 µg/mL reaction concentration. 
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3.2.6 Characterization of Later-Stage Fractions 
Three later-stage fractions were selected for further analysis based on their high 
relative inhibition at 25 µg/mL. Each fraction underwent an experiment favoring 
Michaelis-Menten conditions; examining the MCOD reaction at variable 7-
methoxycoumarin concentration in the presence and absence of the fraction of interest. 
This type of experiment can give both qualitative and quantitative analysis of these 
fractions, both in terms of their inhibition type and Ki value, respectively. 
When a compound inhibits an enzyme, it will induce a change in either the Vmax 
and/or Km of the substrate reaction. By observing the apparent Km (Km
app
) and Vmax 
(Vmax
app
) of the inhibited reaction, one can determine the type of inhibition (competitive, 
non-competitive, and uncompetitive) and Ki of the inhibitor. Ki is a dissociation constant 
that is defined as the concentration of compound needed to induce inhibition. 
 78-D, which initially showed 74.2 % reduction of MCOD activity at 25 µg/mL, 
was the first to undergo analysis. The MCOD reaction was carried out with 5-400 µM 
substrate concentration in the presence of 25 µg/mL of 78-D. These results were 
compared to a standard curve generated from MCOD assay under normal conditions. 
Results from these two reaction conditions were plotted, as seen on Figure 29. The Vmax 
of the reaction was greatly reduced, dropping from 7.76 x 10
4
 activity units/mg of 
protein/minute to a Vmax
app
 of 3.78 x 10
4
 activity units/mg of protein/minute in the 
presence of 78-D. The Km values of the reaction stayed in comparable ranges, with Km at 
28.6 µM and Km
app
 at 23.4 µM. Non-competitive inhibition, in which the Vmax is reduced 
while the Km remains the same, is implicated in this analysis. This type of inhibition is 
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characterized by the binding of the inhibitor onto an allosteric site on the enzyme.  As 
seen in Equation 2, the Ki of a non-completive inhibitor is calculated based on the change 
in Vmax. Using this equation, the Ki of 78-D was determined to be 24 µg/mL. 
 
Figure 29.  Michaelis-Menten Curves for MCOD in Presence of 78-D. 
 
 
Vmax/ Vmax
app  = 1 + [I]/Ki 
Equation 2. Equation for Calculating Ki of Non-Competitive Inhibitors.  
 
 
Additionally, examination undertaken by the Oberlies Group revealed that the 
contents of the 78-D fraction contained a single compound. Based on an LC/MS and 
NMR profile, the primary compound in 78-D was estimated to be 1-9-hexadecenoate 
(328.26 amu), an unsaturated fatty acid seen in Figure 30. Since this fraction was tested at 
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25 µg/mL, the approximate concentration of the fatty acid in the reaction was 76 µM. 
The Ki value of 78-D, based on this concentration, is calculated to be 73 µM. 
 
Figure 30. Proposed Structure of Major Constituent of 78-D.  
 
 
Both 82-C and 82-D underwent the same type of Michaelis-Menten analysis as 
described above. The MCOD assay, with substrate concentrations ranging from 5-400 
µM, was tested in the presence and absence of each fraction at 25 µg/mL. The results, 
seen in Figure 31, show a marked decrease in the Vmax and Km when either fraction is 
present. The standard curve gave a Vmax of 7.94 x 10
4
 activity units/mg of protein/minute 
and a Km of 84.9 µM. With the 82-C fraction present, the Vmax
app 
was 3.54 x 10
4
 activity 
units/mg of protein/minute and the Km
app
 was 31.8 µM. In the presence of 82-D, the 
Vmax
app
 was 4.44 x 10
4 
activity units/mg of protein/minute while the Km
app
 was 40.4 µM.  
Based on the decrease in both the Vmax and Km of the MCOD assay, these fractions show 
uncompetitive-type inhibition. Since uncompetitive inhibition affects both the Vmax and 
Km, the Ki can be calculated using either equation in Equation 3. Using these equations, 
the Ki ranged between 15-20 µg/mL for 82-C and 23-32 µg/m for 82-D. 
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Figure 31. Michaelis-Menten Curves for MCOD in Presence of 82-C and 82-D. 
 
 
Vmax/ Vmax
app  = 1 + [I]/Ki                Km/ Km
app  = 1 + [I]/Ki 
Equation 3. Equations for Calculating Ki for Uncompetitive Inhibitors. 
 
 
Ki values offer insight into the inhibitory effects of natural products. When 
examining Ki, lower values indicate stronger inhibition against higher values. 
Historically, compounds with Ki values < 10 µM are considered strong inhibitors, and are 
more likely to be linked to herbal-drug interactions
66
. Bergamottin, a strong CYP3A4-
inhibitor found in grapefruit juice, was shown to have a Ki as low as 7.7 µM
67
. The 78-D 
fraction has a Ki of 73 µM, a ten-fold increase when compared to bergamottin. 78-D is 
similar to the reported Ki value of curcumin (76 µM), a considerably weak inhibitor of 
the 7-pentoxyresorufuin O-dealkyation assay
68
. Additionally, the Ki values of 82-C (15-
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20 µg/mL) and 82-D (23-32 µg/mL) can be compared to a similar study, where ginkgo 
biloba extracts showed inhibition of human CYP2C9 at a Ki of 14.8 µg/mL
69
. While 
these findings demonstrated potential of herbal-drug interactions, subsequent in vivo 
studies showed that ginkgo biloba had no effect on the pharmacokinetics of several 
CYP2C9 probes
70,71
. Such comparisons give indication that these later-stage acai berry 
fractions, while demonstration remarkable in vitro inhibition, are not likely to have an 
observable effect on in vivo drug metabolism. 
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CHAPTER IV 
CONCLUSIONS 
 
 
The crude acai berry fractions yielded no remarkable inhibition of both the 
erythromycin N-demethylation (CYP3A4) and dextromethorphan O-demethylation 
(CYP2D6) reactions. It is important to uncover possible interactions with these isoforms, 
given the pharmacological importance these enzymes exhibit. These results are further 
rationalized by the lack of inhibition observed by the butanol fraction. As previously 
discussed, anthocyanins are a major class of constituents in the acai berry and reside in 
the butanol extract. Dreiseitel et. al. had previously found these compounds to be weak 
inhibitors of both CYP3A4
37
 and 2D6
65
, which corresponds to the results of this study. 
Additionally, the peak serum levels of anthocyanins were estimated to be 1.1-2.0 
ng/mL
36
. Given that the crude fractions were tested at 200 µg/mL, it is unlikely that the 
concentration of anthocyanins in the acai berry would have any pharamcokinetic impact 
on these enzymes. Thus, the results of this in vitro study imply that the acai berry does 
not interact with the metabolic activity of cytochrome P450 3A4 and 2D6. 
For the 7-methoxycoumarin O-demethylation reaction, the chloroform extract 
demonstrated a remarkable 95% reduction in activity. Throughout the course of this 
study, the chloroform extract underwent several rounds of inhibition-directed 
fractionation. Scheme 9 gives a detailed summary of the results from screening the acai 
berry extracts, highlighting fractions based on their inhibition of MCOD activity. 
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Scheme 9. Summary of Bioassay Guided Fractionation of MCOD Inhibition. Fractionation of the acai berry 
powder via observed reduction in 7-methoxycoumarin O-demethylation activity in the presence of human 
hepatic S9 fractions. 
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As discussed in the Results and Discussion section, several later-stage fractions 
underwent further experimentation. During this phase of the study, the major constituent 
in the 78-D fraction was determined to be 1-9-hexadecenoate (Figure 32), a 
monounsaturated fatty acid. A large number of CYP450 isoforms participate in the 
endogenous metabolism of lipids in the body. For example, CYP2E1 is responsible for 
the activation of arachidonic acid, the polyunsaturated fatty acid precursor to a variety of 
CNS signaling molecules, and epoxyeicosatrienoic acid, a vasodilation and anti-
inflammatory signaling precursor
72
. However, it should be noted that the role fatty acids 
play in cytochrome P450 inhibition has not been thoroughly studied. Yao et al recently 
investigated a wide range of fatty acids for CYP450 inhibition. Results from this study 
showed that the polyunsaturated fatty acids arachidonic acid, eicosapentaenoic acid, and 
docosahexaenoic acid were potent inhibitors of CYP2C9 and 2C19 (Ki<5 µM) and weak 
inhibitors of CYP3A4, 1A2, and 2E1 (Ki >10 µM)
73
. Given the relatively high Ki of 1-9-
hexadecenoate (73 µM), it can be classified as a weak inhibitor of human cytochrome 
P450. Future studies might reveal constituents in the acai berry with more potent 
inhibition. 
The 7-methoxycoumarin O-demethylation assay proved to be useful tool for the 
non-selective screening several human cytochrome P450 isoforms. With the implication 
that the acai berry inhibits these CYP450 isoforms, there exists a potential for 
innumerable herbal-drug interactions. Studies have shown that the CYP1A2 metabolism 
of warfarin, an anticoagulant, is susceptible to large number of botanical interactions, 
including soy milk
74
, ginseng
75
, and foods rich in vitamin k1
76
. Hemorrhaging results 
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from an increase in international normalization ratio (INR), which is a measure of the 
tendency for blood to clot and is directly affected by warfarin bioavailability
77
. Inhibition 
of CYP2E1 metabolism can actually prevent adverse effects on the body. Most notably, 
CYP2E1 oxidation of acetaminophen can result in the formation of N-acetyl-p-
benzoquininemine, a hepatotoxic metabolite. Inhibition of 2E1 would be beneficial when 
a high dosage of acetaminophen is present in the body
78
.  
In summary, weak interactions have been observed using the general CYP450 
probe substrate 7-methoxycoumarin, and several fractions have been identified as 
potential inhibitors, one being identified as a fatty acid with a Ki of approximately 
73M. The current study also demonstrates that acai berry fractions do not appear to 
interact substantially with the two major drug metabolizing families 3A and 2D, which 
metabolize a large percentage of all pharmaceuticals on the market, and this suggests a 
low potential for adverse drug interactions related to consumption of acai berry products.  
Additional studies are currently on-going to address P450 isoforms that were not 
represented in this study.   
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